Through fostering strong, collaborative relationships with members of the medical community who share our dedication to dermatology and commitment to improving the lives the of those impacted, we strive to address unmet needs in the field and continue to further the UCB dermatology foundation.
Rhonda Peebles, Head of U.S. Dermatology
Our Solid Foundation
Our approach to discovering, developing, and delivering highly differentiated medicines starts and ends with the people who need it the most. UCB’s goal is to enable affordable access to our medicines for all people who need them in a way that is sustainable for patients, society, and UCB.
Our Diverse & Evolving Portfolio
Across dermatology, we have a rich portfolio and pipeline developed to serve people living with chronic inflammatory conditions with high unmet needs. Our work spans across the dermatologic space, including diseases such as PSO, HS, and atopic dermatitis.
Meaningful and Trusted Long-term Partnerships
UCB maintains deep connections with patient and scientific communities within dermatology to drive innovation and ensure our work has the greatest possible impact, now and into the future.
We have established enduring partnerships with advocacy groups to reach and support the communities most impacted by these severe diseases, including collaborations with:
UCB also supports disease-state healthcare provider and patient campaigns to raise awareness and provide resources that support management of immune-mediated diseases, including:
- The Make HStory campaign around HS
- The HS Coalition
-A multi-stakeholder group of leading advocates and healthcare professionals assembled to address the health inequities people living with HS face, and to help transform the policy and access landscape in the United States
Harnessing Innovative Technology and Trailblazing Science
Across Immunology, we are embedding cutting-edge technologies and digital innovation into everyday care for people with chronic inflammatory diseases to deliver a personalized experience, accelerate early intervention, and reduce time to diagnosis. We are standardizing higher treatment thresholds as primary and secondary endpoints in our active Immunology clinical trial programs. These stringent standards support our aim of bringing best-in-disease treatment options to the community and preventing disease progression in people with moderate-to-severe diseases.
At UCB, we know that understanding the experiences of those impacted by diseases like PSO and HS is the first step to developing solutions that improve lives.
